Mainz Biomed Signs on Praxisdienst for Distribution of Colorectal Cancer Test in Germany

Feb 22, 2024 | staff reporter

NEW YORK — Mainz Biomed said on Thursday that it has signed an agreement for the distribution of its ColoAlert at-home colorectal cancer screening test in Germany with Praxisdienst.

According to Mainz, Praxisdienst is Germany's largest online medical products retailer. Financial and other terms of the deal were not disclosed.

ColoAlert analyzes stool samples collected at home, combining PCR-based DNA and RNA analysis with fecal immunohistochemistry for the early detection of colorectal cancer and precancerous lesions.

Earlier this week, Mainz inked a similar distribution pact with TomaLab for Italy. The German company also recently released positive interim data on a next-generation version of the assay.

Mainz Biomed was the other company with a high performing DNA/mRNA CRC (stool test) that has high clinical performance with 94% sensitivity and 97% specificity AND 80% sensitivity for AA. One way or the other these next generation stool based DNA tests that can demonstrate far superior clinical performance than FIT & FOBT are still being adopted commercially.

It shall be interesting to see where they price this when it gets listed on the Praxisdienst website, my guess from looking at their website it will be less than €50/60